Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 568

1.

Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.

Singh S, Willig JH, Mugavero MJ, Crane PK, Harrington RD, Knopp RH, Kosel BW, Saag MS, Kitahata MM, Crane HM.

Clin Infect Dis. 2011 Feb 1;52(3):387-95. doi: 10.1093/cid/ciq111. Epub 2010 Dec 28.

2.
3.
4.

Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.

Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.

Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.

6.

The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.

Fonseca FA, Ruiz A, Cardona-Muñoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY PENTA investigators.

Curr Med Res Opin. 2005 Aug;21(8):1307-15.

PMID:
16083541
7.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946
8.

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.

Pharmacotherapy. 2006 Apr;26(4):469-78.

PMID:
16553504
9.

Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.

Mazza F, Stefanutti C, Di Giacomo S, Vivenzio A, Fraone N, Mazzarella B, Bucci A.

Am J Cardiovasc Drugs. 2008;8(4):265-70.

PMID:
18690760
10.

Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.

Bullano MF, Kamat S, Wertz DA, Borok GM, Gandhi SK, McDonough KL, Willey VJ.

Am J Health Syst Pharm. 2007 Feb 1;64(3):276-84.

PMID:
17244877
11.

Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.

Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M; Kishiwada Atherosclerosis Prevention Study (KAPS) Group.

Cardiovasc Ther. 2014 Jun;32(3):97-104. doi: 10.1111/1755-5922.12066.

PMID:
24456217
12.

Effect of two intensive statin regimens on progression of coronary disease.

Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE.

N Engl J Med. 2011 Dec 1;365(22):2078-87. doi: 10.1056/NEJMoa1110874. Epub 2011 Nov 15.

13.

Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.

Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS.

Am Heart J. 2006 May;151(5):975.e1-9.

PMID:
16644314
14.

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW; STELLAR Study Group.

Am J Cardiol. 2003 Jul 15;92(2):152-60.

PMID:
12860216
15.

Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.

Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group.

Am Heart J. 2004 Apr;147(4):705-13.

PMID:
15077101
16.

Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.

Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.

Am Heart J. 2004 Jul;148(1):e4.

PMID:
15215813
17.

Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.

Calza L, Manfredi R, Colangeli V, Pocaterra D, Pavoni M, Chiodo F.

Curr HIV Res. 2008 Nov;6(6):572-8.

PMID:
18991624
18.

Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).

Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group.

Am J Cardiol. 2007 Jun 1;99(11):1538-43. Epub 2007 Apr 16.

PMID:
17531577
19.

Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.

Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H.

Int J Cardiol. 2005 Apr 20;100(2):309-16.

PMID:
15823640
20.

Supplemental Content

Support Center